The intramuscular vaccine is developed to prevent diseases caused by two strains each of seasonal flu virus subtypes A and type B.
GSK North America vaccines clinical development and medical affairs vice president and head Dr. Leonard Friedland said the predominant circulating influenza B strain was not the strain that public health authorities selected in six of the last 11 flu seasons.
"Fluarix Quadrivalent will help protect individuals against both B strains and from a public-health standpoint, can help decrease the burden of disease," Friedland added.
The company anticipates in time vaccine availability for the 2013-2014 flu season besides completion of orders for its trivalent vaccines.
At Present, Fluarix Quadrivalent is not approved or licensed in any region other than the US.